CRISPR THERAPEUTICS AG (CRSP) Fundamental Analysis & Valuation

NASDAQ:CRSP • CH0334081137

Current stock price

51.19 USD
-1.15 (-2.2%)
Last:

This CRSP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CRSP Profitability Analysis

1.1 Basic Checks

  • In the past year CRSP has reported negative net income.
  • CRSP had a negative operating cash flow in the past year.
  • CRSP had negative earnings in 4 of the past 5 years.
  • CRSP had negative operating cash flow in 4 of the past 5 years.
CRSP Yearly Net Income VS EBIT VS OCF VS FCFCRSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M -600M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -25.67%, CRSP is in the better half of the industry, outperforming 69.90% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -30.26%, CRSP is in the better half of the industry, outperforming 74.95% of the companies in the same industry.
Industry RankSector Rank
ROA -25.67%
ROE -30.26%
ROIC N/A
ROA(3y)-16.3%
ROA(5y)-12.83%
ROE(3y)-19.13%
ROE(5y)-15.26%
ROIC(3y)N/A
ROIC(5y)N/A
CRSP Yearly ROA, ROE, ROICCRSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30 -40

1.3 Margins

  • CRSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRSP Yearly Profit, Operating, Gross MarginsCRSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CRSP Health Analysis

2.1 Basic Checks

  • CRSP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CRSP has more shares outstanding
  • Compared to 5 years ago, CRSP has more shares outstanding
  • CRSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRSP Yearly Shares OutstandingCRSP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
CRSP Yearly Total Debt VS Total AssetsCRSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • An Altman-Z score of 7.72 indicates that CRSP is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 7.72, CRSP is doing good in the industry, outperforming 77.86% of the companies in the same industry.
  • There is no outstanding debt for CRSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.72
ROIC/WACCN/A
WACC4.96%
CRSP Yearly LT Debt VS Equity VS FCFCRSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 13.32 indicates that CRSP has no problem at all paying its short term obligations.
  • CRSP has a better Current ratio (13.32) than 87.57% of its industry peers.
  • CRSP has a Quick Ratio of 13.32. This indicates that CRSP is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 13.32, CRSP belongs to the top of the industry, outperforming 87.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.32
Quick Ratio 13.32
CRSP Yearly Current Assets VS Current LiabilitesCRSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. CRSP Growth Analysis

3.1 Past

  • CRSP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.80%.
  • The Revenue for CRSP has decreased by -90.59% in the past year. This is quite bad
  • The Revenue has been growing by 38.05% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-23.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-211.36%
Revenue 1Y (TTM)-90.59%
Revenue growth 3Y43.01%
Revenue growth 5Y38.05%
Sales Q2Q%-97.58%

3.2 Future

  • CRSP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.06% yearly.
  • The Revenue is expected to grow by 282.39% on average over the next years. This is a very strong growth
EPS Next Y7.21%
EPS Next 2Y11.06%
EPS Next 3Y17.37%
EPS Next 5Y39.06%
Revenue Next Year328.07%
Revenue Next 2Y241.55%
Revenue Next 3Y333%
Revenue Next 5Y282.39%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRSP Yearly Revenue VS EstimatesCRSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
CRSP Yearly EPS VS EstimatesCRSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

0

4. CRSP Valuation Analysis

4.1 Price/Earnings Ratio

  • CRSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRSP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRSP Price Earnings VS Forward Price EarningsCRSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRSP Per share dataCRSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • CRSP's earnings are expected to grow with 17.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.06%
EPS Next 3Y17.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRSP Dividend Analysis

5.1 Amount

  • No dividends for CRSP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRSP Fundamentals: All Metrics, Ratios and Statistics

CRISPR THERAPEUTICS AG

NASDAQ:CRSP (5/1/2026, 10:11:46 AM)

51.19

-1.15 (-2.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)02-12
Earnings (Next)05-11
Inst Owners73.29%
Inst Owner Change0%
Ins Owners1.53%
Ins Owner Change-0.39%
Market Cap4.91B
Revenue(TTM)3.51M
Net Income(TTM)-581.60M
Analysts77.14
Price Target82.88 (61.91%)
Short Float %24.92%
Short Ratio11.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.7%
Min EPS beat(2)-16.43%
Max EPS beat(2)9.04%
EPS beat(4)2
Avg EPS beat(4)-5.01%
Min EPS beat(4)-23.86%
Max EPS beat(4)11.23%
EPS beat(8)5
Avg EPS beat(8)9.09%
EPS beat(12)9
Avg EPS beat(12)365.88%
EPS beat(16)11
Avg EPS beat(16)275.71%
Revenue beat(2)0
Avg Revenue beat(2)-85.12%
Min Revenue beat(2)-90.21%
Max Revenue beat(2)-80.03%
Revenue beat(4)0
Avg Revenue beat(4)-85.8%
Min Revenue beat(4)-90.21%
Max Revenue beat(4)-80.03%
Revenue beat(8)1
Avg Revenue beat(8)-34.33%
Revenue beat(12)4
Avg Revenue beat(12)326.68%
Revenue beat(16)4
Avg Revenue beat(16)222.98%
PT rev (1m)-1.66%
PT rev (3m)14.57%
EPS NQ rev (1m)0.3%
EPS NQ rev (3m)-11.31%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-20.77%
Revenue NQ rev (1m)42.62%
Revenue NQ rev (3m)11.32%
Revenue NY rev (1m)-23.24%
Revenue NY rev (3m)-72.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1399.92
P/FCF N/A
P/OCF N/A
P/B 2.56
P/tB 2.56
EV/EBITDA N/A
EPS(TTM)-5.41
EYN/A
EPS(NY)-5.02
Fwd EYN/A
FCF(TTM)-3.86
FCFYN/A
OCF(TTM)-3.59
OCFYN/A
SpS0.04
BVpS20.02
TBVpS20.02
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -25.67%
ROE -30.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.3%
ROA(5y)-12.83%
ROE(3y)-19.13%
ROE(5y)-15.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 133.04%
Cap/Sales 738.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.32
Quick Ratio 13.32
Altman-Z 7.72
F-Score2
WACC4.96%
ROIC/WACCN/A
Cap/Depr(3y)67.75%
Cap/Depr(5y)162.17%
Cap/Sales(3y)248.87%
Cap/Sales(5y)771.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-211.36%
EPS Next Y7.21%
EPS Next 2Y11.06%
EPS Next 3Y17.37%
EPS Next 5Y39.06%
Revenue 1Y (TTM)-90.59%
Revenue growth 3Y43.01%
Revenue growth 5Y38.05%
Sales Q2Q%-97.58%
Revenue Next Year328.07%
Revenue Next 2Y241.55%
Revenue Next 3Y333%
Revenue Next 5Y282.39%
EBIT growth 1Y-21.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.05%
EBIT Next 3Y13.56%
EBIT Next 5Y17.21%
FCF growth 1Y-156.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-141.65%
OCF growth 3YN/A
OCF growth 5YN/A

CRISPR THERAPEUTICS AG / CRSP Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CRISPR THERAPEUTICS AG?

ChartMill assigns a fundamental rating of 4 / 10 to CRSP.


What is the valuation status for CRSP stock?

ChartMill assigns a valuation rating of 0 / 10 to CRISPR THERAPEUTICS AG (CRSP). This can be considered as Overvalued.


How profitable is CRISPR THERAPEUTICS AG (CRSP) stock?

CRISPR THERAPEUTICS AG (CRSP) has a profitability rating of 1 / 10.


How financially healthy is CRISPR THERAPEUTICS AG?

The financial health rating of CRISPR THERAPEUTICS AG (CRSP) is 8 / 10.


Can you provide the expected EPS growth for CRSP stock?

The Earnings per Share (EPS) of CRISPR THERAPEUTICS AG (CRSP) is expected to grow by 7.21% in the next year.